Abstract

Organizations both in the United States and globally have advocated for screening for chronic kidney disease with a urine test for proteinuria followed by subsequent testing with creatinine-based estimated glomerular filtration rate determinations. Screening for a disease, such as chronic kidney disease, can have value, but a decision to screen is not a trivial decision. Criteria must be met to balance the aggregate benefits with the risks and costs of a screening test. We discuss how screening for chronic kidney disease meets many of these criteria, but also how the populations to which it is applied must be targeted and the strategies for testing must be clearly defined.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.